Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Oncogene Proteins, Fusion"" wg kryterium: Temat


Tytuł :
Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
Autorzy :
Ommer J; Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Selfe JL; Sarcoma Molecular Pathology Laboratory, The Institute of Cancer Research, London, United Kingdom.
Wachtel M; Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
O'Brien EM; Sarcoma Molecular Pathology Laboratory, The Institute of Cancer Research, London, United Kingdom.
Laubscher D; Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Roemmele M; Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Kasper S; Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Delattre O; France INSERM U830, Équipe Labellisé LNCC, PSL Université, SIREDO Oncology Centre, Institut Curie, Paris, France.
Surdez D; France INSERM U830, Équipe Labellisé LNCC, PSL Université, SIREDO Oncology Centre, Institut Curie, Paris, France.
Petts G; Department of Diagnostic Paediatric Histopathology, Royal Manchester Children's Hospital, Manchester, United Kingdom.
Kelsey A; Department of Diagnostic Paediatric Histopathology, Royal Manchester Children's Hospital, Manchester, United Kingdom.
Shipley J; Sarcoma Molecular Pathology Laboratory, The Institute of Cancer Research, London, United Kingdom.
Schäfer BW; Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2020 Feb 15; Vol. 80 (4), pp. 832-842. Date of Electronic Publication: 2019 Dec 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Aurora Kinase A/*metabolism
N-Myc Proto-Oncogene Protein/*metabolism
Oncogene Proteins, Fusion/*metabolism
Paired Box Transcription Factors/*metabolism
Rhabdomyosarcoma, Alveolar/*drug therapy
Aniline Compounds/pharmacology ; Aniline Compounds/therapeutic use ; Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Apoptosis/drug effects ; Aurora Kinase A/antagonists & inhibitors ; Drug Synergism ; Gene Knockdown Techniques ; HEK293 Cells ; Humans ; Mice ; Mutagenesis, Site-Directed ; Oncogene Proteins, Fusion/genetics ; Paired Box Transcription Factors/genetics ; Phosphorylation/drug effects ; Primary Cell Culture ; Protein Stability/drug effects ; Proto-Oncogene Proteins c-bcl-2/metabolism ; RNA, Small Interfering/metabolism ; Rhabdomyosarcoma, Alveolar/genetics ; Rhabdomyosarcoma, Alveolar/pathology ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Autorzy :
Baba M; Laboratory of Cancer Metabolism, International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan. .; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Furuya M; Department of Molecular Pathology, Yokohama City University, Yokohama, Japan.
Motoshima T; Department of Urology, Kumamoto University, Kumamoto, Japan.
Lang M; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Funasaki S; Laboratory of Cancer Metabolism, International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.
Ma W; Laboratory of Cancer Metabolism, International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.
Sun HW; Biodata Mining and Discovery Section, NIAMS, NIH, Bethesda, Maryland.
Hasumi H; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.; Department of Urology, Yokohama City University, Yokohama, Japan.
Huang Y; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Kato I; Department of Molecular Pathology, Yokohama City University, Yokohama, Japan.
Kadomatsu T; Department of Molecular Genetics, Kumamoto University, Kumamoto, Japan.
Satou Y; Laboratory of Retroviral Genomics and Transcriptomics, International Research Center for Medical Sciences (IRCMS), Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
Morris N; Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Karim BO; Pathology/Histotechnology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Ileva L; Small Animal Imaging Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Kalen JD; Small Animal Imaging Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Wilan Krisna LA; Laboratory of Cancer Metabolism, International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.
Hasumi Y; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Sugiyama A; DSK Project, Medical Innovation Center, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan.
Kurahashi R; Department of Urology, Kumamoto University, Kumamoto, Japan.; Department of Molecular Genetics, Kumamoto University, Kumamoto, Japan.
Nishimoto K; Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Oyama M; Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Nagashima Y; Department of Surgical Pathology, Tokyo Women's Medical University, Tokyo, Japan.
Kuroda N; Department of Pathology, Kochi Red Cross Hospital, Kochi, Japan.
Araki K; Division of Developmental Genetics, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
Eto M; Department of Urology, Kyushyu University, Fukuoka, Japan.
Yao M; Department of Urology, Yokohama City University, Yokohama, Japan.
Kamba T; Department of Urology, Kumamoto University, Kumamoto, Japan.
Suda T; Laboratory of Stem Cell Regulation, International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.; Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, Singapore.
Oike Y; Department of Molecular Genetics, Kumamoto University, Kumamoto, Japan.
Schmidt LS; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. .; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Linehan WM; Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. .
Pokaż więcej
Źródło :
Molecular cancer research : MCR [Mol Cancer Res] 2019 Aug; Vol. 17 (8), pp. 1613-1626. Date of Electronic Publication: 2019 May 01.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Chromosomes, Human, X*
Oncogene Proteins, Fusion*
Translocation, Genetic*
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/*genetics
Carcinoma, Renal Cell/*pathology
Kidney Neoplasms/*pathology
Membrane Glycoproteins/*metabolism
Adolescent ; Adult ; Aged ; Animals ; Apoptosis ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Carcinoma, Renal Cell/genetics ; Carcinoma, Renal Cell/metabolism ; Cell Cycle Proteins/genetics ; Cell Proliferation ; Child ; Disease Models, Animal ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Kidney Neoplasms/genetics ; Kidney Neoplasms/metabolism ; Male ; Membrane Glycoproteins/genetics ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Neoplasm Proteins/genetics ; Prognosis ; Survival Rate ; Tumor Cells, Cultured ; Young Adult
Czasopismo naukowe
Tytuł :
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
Autorzy :
Cocco E; Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Benhamida J; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Middha S; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Zehir A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Mullaney K; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Shia J; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Yaeger R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Zhang L; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Wong D; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Villafania L; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Nafa K; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Scaltriti M; Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Drilon A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York.
Saltz L; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Schram AM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York.
Stadler ZK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Hyman DM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York.
Benayed R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ladanyi M; Human Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Hechtman JF; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2019 Mar 15; Vol. 79 (6), pp. 1047-1053. Date of Electronic Publication: 2019 Jan 14.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA Methylation*
Biomarkers, Tumor/*analysis
Colorectal Neoplasms/*genetics
MutL Protein Homolog 1/*genetics
Oncogene Proteins, Fusion/*analysis
Proto-Oncogene Proteins B-raf/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; Colorectal Neoplasms/pathology ; Female ; Follow-Up Studies ; Humans ; Male ; Microsatellite Instability ; Middle Aged ; Mutation ; Neoplasm Metastasis ; Oncogene Proteins, Fusion/genetics ; Prognosis ; Promoter Regions, Genetic
Czasopismo naukowe
Tytuł :
Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.
Autorzy :
Davis LE; Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon. .; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Oregon Health and Sciences University, Portland, Oregon.
Nusser KD; Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon.
Przybyl J; Department of Pathology; Stanford University School of Medicine, Stanford, California.
Pittsenbarger J; Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon.
Hofmann NE; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Oregon Health and Sciences University, Portland, Oregon.
Varma S; Department of Pathology; Stanford University School of Medicine, Stanford, California.
Vennam S; Department of Pathology; Stanford University School of Medicine, Stanford, California.
Debiec-Rychter M; Department of Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
van de Rijn M; Department of Pathology; Stanford University School of Medicine, Stanford, California.
Davare MA; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Oregon Health and Sciences University, Portland, Oregon. .
Pokaż więcej
Źródło :
Molecular cancer research : MCR [Mol Cancer Res] 2019 Mar; Vol. 17 (3), pp. 676-685. Date of Electronic Publication: 2018 Dec 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anaplastic Lymphoma Kinase/*genetics
Leiomyosarcoma/*genetics
Oncogene Proteins, Fusion/*genetics
Anaplastic Lymphoma Kinase/metabolism ; Animals ; Cell Line, Tumor ; Gene Fusion ; Humans ; Intracellular Signaling Peptides and Proteins/genetics ; Intracellular Signaling Peptides and Proteins/metabolism ; Lactams, Macrocyclic/pharmacology ; Leiomyosarcoma/enzymology ; Leiomyosarcoma/pathology ; Mice ; NIH 3T3 Cells ; Oncogene Proteins, Fusion/metabolism ; Protein Kinase Inhibitors/pharmacology ; Transfection
Czasopismo naukowe
Tytuł :
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
Autorzy :
Neel DS; Department of Medicine, University of California at San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
Allegakoen DV; Department of Medicine, University of California at San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
Olivas V; Department of Medicine, University of California at San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
Mayekar MK; Department of Medicine, University of California at San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
Hemmati G; Department of Medicine, University of California at San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
Chatterjee N; Department of Medicine, University of California at San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
Blakely CM; Department of Medicine, University of California at San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
McCoach CE; Department of Medicine, University of California at San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
Rotow JK; Department of Medicine, University of California at San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
Le A; Department of Medicine, University of Colorado Anschutz Medical Campus, Denver, Colorado.
Karachaliou N; Cancer Biology and Precision Medicine Program Catalan Institute of Oncology Hospital Germans Trias i Pujol Badalona, Barcelona, Spain.
Rosell R; Cancer Biology and Precision Medicine Program Catalan Institute of Oncology Hospital Germans Trias i Pujol Badalona, Barcelona, Spain.
Riess JW; University of California Davis School of Medicine, Sacramento, California.; Comprehensive Cancer Center, Sacramento, California.
Nichols R; Revolution Medicines, Redwood City, California.
Doebele RC; Department of Medicine, University of Colorado Anschutz Medical Campus, Denver, Colorado.
Bivona TG; Department of Medicine, University of California at San Francisco, San Francisco, California. .; Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2019 Feb 01; Vol. 79 (3), pp. 546-556. Date of Electronic Publication: 2018 Dec 11.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma of Lung/*metabolism
Lung Neoplasms/*metabolism
Oncogene Proteins, Fusion/*metabolism
Protein-Tyrosine Kinases/*metabolism
Proto-Oncogene Proteins/*metabolism
Adenocarcinoma of Lung/enzymology ; Adenocarcinoma of Lung/genetics ; Adenocarcinoma of Lung/pathology ; Animals ; Antigens, CD/genetics ; Antigens, CD/metabolism ; Endosomes/metabolism ; HEK293 Cells ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; MAP Kinase Signaling System ; Mice ; Mice, Inbred NOD ; Mice, SCID ; NIH 3T3 Cells ; Oncogene Proteins, Fusion/genetics ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/genetics ; Sialyltransferases/genetics ; Sialyltransferases/metabolism ; Sodium-Phosphate Cotransporter Proteins, Type IIb/genetics ; Sodium-Phosphate Cotransporter Proteins, Type IIb/metabolism ; Subcellular Fractions/metabolism ; Syndecan-4/genetics ; Syndecan-4/metabolism ; ras Proteins/genetics ; ras Proteins/metabolism
Czasopismo naukowe
Tytuł :
ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.
Autorzy :
Childress MA; Cancer Biology Program, Vanderbilt University, Nashville, Tennessee.
Himmelberg SM; Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Chen H; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Deng W; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Davies MA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Lovly CM; Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee. .; Vanderbilt Ingram Cancer Center, Nashville, Tennessee.
Pokaż więcej
Źródło :
Molecular cancer research : MCR [Mol Cancer Res] 2018 Nov; Vol. 16 (11), pp. 1724-1736. Date of Electronic Publication: 2018 Jul 12.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Anaplastic Lymphoma Kinase/*antagonists & inhibitors
Oncogene Proteins, Fusion/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Anaplastic Lymphoma Kinase/genetics ; Anaplastic Lymphoma Kinase/metabolism ; Animals ; Cell Line, Tumor ; Mice ; NIH 3T3 Cells ; Oncogene Proteins, Fusion/genetics ; Oncogene Proteins, Fusion/metabolism ; Phenotype
Czasopismo naukowe
Tytuł :
"Z4" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism.
Autorzy :
Shiota H; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Elya JE; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Alekseyenko AA; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.; Department of Genetics, Harvard Medical School, Boston, Massachusetts.
Chou PM; Department of Pathology and Laboratory Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Gorman SA; Cancer Epigenetics DPU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
Barbash O; Cancer Epigenetics DPU, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
Becht K; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Danga K; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Kuroda MI; Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.; Department of Genetics, Harvard Medical School, Boston, Massachusetts.
Nardi V; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
French CA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. .
Pokaż więcej
Źródło :
Molecular cancer research : MCR [Mol Cancer Res] 2018 Dec; Vol. 16 (12), pp. 1826-1833. Date of Electronic Publication: 2018 Aug 23.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Squamous Cell/*genetics
DNA-Binding Proteins/*genetics
Neoplasm Proteins/*genetics
Nuclear Proteins/*genetics
Oncogene Proteins, Fusion/*genetics
Tumor Suppressor Proteins/*metabolism
Adolescent ; Cell Line, Tumor ; Cell Nucleus/genetics ; Cell Nucleus/metabolism ; Cell Survival ; DNA-Binding Proteins/metabolism ; Female ; High-Throughput Nucleotide Sequencing ; Humans ; In Situ Hybridization, Fluorescence ; Neoplasm Proteins/metabolism ; Nuclear Proteins/metabolism ; Oncogene Proteins, Fusion/metabolism ; Sequence Analysis, DNA
Czasopismo naukowe
Tytuł :
A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status.
Autorzy :
Stopsack KH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. .; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Gonzalez-Feliciano AG; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Peisch SF; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Downer MK; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Gage RA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Finn S; Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Trinity College Dublin, Dublin, Ireland.
Lis RT; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Graff RE; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
Pettersson A; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Department of Medicine, Clinical Epidemiology Unit, Solna, Karolinska Institutet, Stockholm, Sweden.
Pernar CH; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Loda M; Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Kantoff PW; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Ahearn TU; National Cancer Institute, Division of Cancer Epidemiology and Genetics, Epidemiology and Biostatistics Program, Bethesda, Maryland.
Mucci LA
Pokaż więcej
Corporate Authors :
Transdisciplinary Prostate Cancer Partnership (ToPCaP)
Źródło :
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2018 Oct; Vol. 27 (10), pp. 1231-1233. Date of Electronic Publication: 2018 Aug 14.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
Aspirin/*therapeutic use
Oncogene Proteins, Fusion/*metabolism
Prostatic Neoplasms/*epidemiology
Adult ; Aged ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Oncogene Proteins, Fusion/genetics ; Prognosis ; Prospective Studies ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; United States/epidemiology
Czasopismo naukowe
Tytuł :
Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.
Autorzy :
Mohamed AA; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland.
Xavier CP; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland.
Sukumar G; Department of Anatomy, Physiology and Genetics, Uniformed Services University of Health Sciences, Bethesda, Maryland.
Tan SH; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland.
Ravindranath L; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland.
Seraj N; Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland.
Kumar V; Division of Radiation & Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
Sreenath T; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland.
McLeod DG; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland.
Petrovics G; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland.; John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland.
Rosner IL; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland.; John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland.; Urology Service, Walter Reed National Military Medical Center, Bethesda, Maryland.
Srivastava M; Department of Anatomy, Physiology and Genetics, Uniformed Services University of Health Sciences, Bethesda, Maryland.; John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland.
Strovel J; Noble Life Sciences, Gaithersburg, Maryland.
Malhotra SV; Division of Radiation & Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
LaRonde NA; Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland.
Dobi A; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland.; John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland.
Dalgard CL; Department of Anatomy, Physiology and Genetics, Uniformed Services University of Health Sciences, Bethesda, Maryland. .; John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland.
Srivastava S; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland. .; John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland.
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2018 Jul 01; Vol. 78 (13), pp. 3659-3671. Date of Electronic Publication: 2018 Apr 30.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Azo Compounds/*pharmacology
Oncogene Proteins, Fusion/*antagonists & inhibitors
Prostatic Neoplasms/*drug therapy
Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Azo Compounds/therapeutic use ; Cell Line, Tumor ; Humans ; Male ; Mice ; Mice, Nude ; Oncogene Proteins, Fusion/genetics ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/pharmacology ; Phenylthiohydantoin/therapeutic use ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/pathology ; Protein-Serine-Threonine Kinases/genetics ; Protein-Serine-Threonine Kinases/metabolism ; RNA, Small Interfering/metabolism ; Small Molecule Libraries ; Transcriptional Regulator ERG/antagonists & inhibitors ; Transcriptional Regulator ERG/genetics ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Height, Obesity, and the Risk of TMPRSS2:ERG -Defined Prostate Cancer.
Autorzy :
Graff RE; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. .; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Ahearn TU; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Pettersson A; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Ebot EM; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Gerke T; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
Penney KL; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Wilson KM; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Markt SC; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Pernar CH; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Gonzalez-Feliciano AG; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Song M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Lis RT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Schmidt DR; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.; Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts.
Vander Heiden MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Fiorentino M; Pathology Unit, Addarii Institute, S. Orsola-Malpighi Hospital, Bologna, Italy.
Giovannucci EL; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Loda M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Mucci LA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Pokaż więcej
Źródło :
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2018 Feb; Vol. 27 (2), pp. 193-200. Date of Electronic Publication: 2017 Nov 22.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Obesity/*complications
Oncogene Proteins, Fusion/*analysis
Prostatic Neoplasms/*etiology
Adult ; Aged ; Body Height ; Body Mass Index ; Body Weight ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Oncogene Proteins, Fusion/genetics ; Oncogene Proteins, Fusion/metabolism ; Prospective Studies ; Prostatic Neoplasms/chemistry ; Prostatic Neoplasms/epidemiology ; Prostatic Neoplasms/genetics ; Risk Factors ; Transcriptional Regulator ERG/analysis
Czasopismo naukowe
Tytuł :
Novel Intergenically Spliced Chimera, NFATC3-PLA2G15 , Is Associated with Aggressive T-ALL Biology and Outcome.
Autorzy :
Bond J; Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de Recherche Médicale (INSERM) U1151, and Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France. .
Tran Quang C; Institut Curie, PSL Research University, CNRS UMR 3348, Orsay, France.; Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, Orsay, France.
Hypolite G; Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de Recherche Médicale (INSERM) U1151, and Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France.
Belhocine M; Technological Advances for Genomics and Clinics (TAGC), INSERM U1090, Aix-Marseille University UMR-S 1090, Marseille, France.
Bergon A; Technological Advances for Genomics and Clinics (TAGC), INSERM U1090, Aix-Marseille University UMR-S 1090, Marseille, France.
Cordonnier G; Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de Recherche Médicale (INSERM) U1151, and Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France.
Ghysdael J; Institut Curie, PSL Research University, CNRS UMR 3348, Orsay, France.; Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, Orsay, France.
Macintyre E; Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de Recherche Médicale (INSERM) U1151, and Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France.
Boissel N; Université Paris Diderot, Institut Universitaire d'Hématologie, EA-3518, Assistance Publique-Hôpitaux de Paris, University Hospital Saint-Louis, Paris, France.
Spicuglia S; Technological Advances for Genomics and Clinics (TAGC), INSERM U1090, Aix-Marseille University UMR-S 1090, Marseille, France.
Asnafi V; Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de Recherche Médicale (INSERM) U1151, and Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France. .
Pokaż więcej
Źródło :
Molecular cancer research : MCR [Mol Cancer Res] 2018 Mar; Vol. 16 (3), pp. 470-475. Date of Electronic Publication: 2018 Jan 12.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Acyltransferases/*genetics
NFATC Transcription Factors/*genetics
Oncogene Proteins, Fusion/*genetics
Phospholipases A2/*genetics
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*genetics
Acyltransferases/metabolism ; Animals ; Chimera ; HEK293 Cells ; Heterografts ; Humans ; Male ; Mice ; NFATC Transcription Factors/metabolism ; Oncogene Proteins, Fusion/metabolism ; Phospholipases A2/metabolism ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/metabolism ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/pathology ; RNA Splicing/genetics ; Survival Analysis
Czasopismo naukowe
Tytuł :
Infection Exposure Promotes ETV6-RUNX1 Precursor B-cell Leukemia via Impaired H3K4 Demethylases.
Autorzy :
Rodríguez-Hernández G; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Hauer J; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
Martín-Lorenzo A; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Schäfer D; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
Bartenhagen C; Department of Computer Science, Bonn-Rhein-Sieg University of Applied Sciences, Sankt Augustin, Germany.
García-Ramírez I; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Auer F; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
González-Herrero I; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Ruiz-Roca L; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Gombert M; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
Okpanyi V; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
Fischer U; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
Chen C; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
Dugas M; Department of Computer Science, Bonn-Rhein-Sieg University of Applied Sciences, Sankt Augustin, Germany.
Bhatia S; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
Linka RM; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany.
Garcia-Suquia M; Departamento de Ciencias Biomédicas y del Diagnóstico, Área de Obstetricia y Ginecología, HUS-Universidad de Salamanca, Salamanca, Spain.
Rascón-Trincado MV; Departamento de Ciencias Biomédicas y del Diagnóstico, Área de Obstetricia y Ginecología, HUS-Universidad de Salamanca, Salamanca, Spain.
Garcia-Sanchez A; Departamento de Ciencias Biomédicas y del Diagnóstico, Área de Obstetricia y Ginecología, HUS-Universidad de Salamanca, Salamanca, Spain.; IBSAL, Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain.
Blanco O; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Anatomía Patológica, Universidad de Salamanca, Salamanca, Spain.
García-Cenador MB; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain.
García-Criado FJ; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain.
Cobaleda C; Centro de Biología Molecular Severo Ochoa, CSIC/Universidad Autónoma de Madrid, Campus de Cantoblanco, Madrid, Spain.
Alonso-López D; Bioinformatics Unit, Cancer Research Center (CSIC-USAL), Salamanca, Spain.
De Las Rivas J; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Bioinformatics Unit, Cancer Research Center (CSIC-USAL), Salamanca, Spain.; Bioinformatics and Functional Genomics Research Group, Cancer Research Center (CSIC-USAL), Salamanca, Spain.
Müschen M; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California.
Vicente-Dueñas C; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Sánchez-García I; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca, Campus M. de Unamuno s/n, Salamanca, Spain.; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Borkhardt A; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2017 Aug 15; Vol. 77 (16), pp. 4365-4377. Date of Electronic Publication: 2017 Jun 19.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Core Binding Factor Alpha 2 Subunit/*metabolism
Histone Demethylases/*metabolism
Oncogene Proteins, Fusion/*metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*microbiology
Animals ; Core Binding Factor Alpha 2 Subunit/biosynthesis ; Core Binding Factor Alpha 2 Subunit/genetics ; Disease Models, Animal ; Hematopoietic Stem Cells ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Inbred CBA ; Mice, Transgenic ; Oncogene Proteins, Fusion/biosynthesis ; Oncogene Proteins, Fusion/genetics ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics
Czasopismo naukowe
Tytuł :
Discovery of Human-Similar Gene Fusions in Canine Cancers.
Autorzy :
Ulvé R; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; BIOTRIAL Pharmacology, Unité de Pharmacologie Preéclinique, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Rault M; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Bahin M; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Lagoutte L; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Abadie J; ONIRIS, AMaROC, Ecole Nationale Vétérinaire, Agroalimentaire et de l'Alimentation Nantes Atlantique, Nantes, France.
De Brito C; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Coindre JM; Institut Bergonié, Bordeaux, France.
Botherel N; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Rousseau A; Département de Pathologie Cellulaire et Tissulaire, CHU, Angers, France.
Wucher V; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Cadieu E; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Thieblemont C; APHP, Hopital Saint-Louis, Hemato-oncologie; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Hitte C; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Cornevin L; Laboratoire de Cytogénétique et Biologie Cellulaire, CHU de Rennes, INSERM, INRA, Univ. Rennes 1, Nutrition Metabolisms and Cancer, Rennes, France.
Cabillic F; Laboratoire de Cytogénétique et Biologie Cellulaire, CHU de Rennes, INSERM, INRA, Univ. Rennes 1, Nutrition Metabolisms and Cancer, Rennes, France.
Bachelot L; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Gilot D; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Hennuy B; GIGA-Genomics, Université de Liège, CHU, 1 Avenue de l'Hopital, Liège, BELGIQUE.
Guillaudeux T; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.; ER OSS440 INSERM, Rennes, France.
Le Goff A; BIOTRIAL Pharmacology, Unité de Pharmacologie Preéclinique, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Derrien T; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France.; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Hédan B; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France. .; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
André C; Univ. Rennes 1, CNRS, Institut de Geéneétique et de Deéveloppement de Rennes (IGDR), UMR6290, Rennes, France. .; UMS 3480 CNRS/US018 INSERM Biosit, Laboratoire Commun Oncotrial, Rennes, France.
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2017 Nov 01; Vol. 77 (21), pp. 5721-5727. Date of Electronic Publication: 2017 Sep 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Dog Diseases/*genetics
Neoplasms/*genetics
Neoplasms/*veterinary
Oncogene Proteins, Fusion/*genetics
Animals ; Base Sequence ; Blotting, Western ; Chromosome Breakpoints ; Dog Diseases/metabolism ; Dogs ; Gene Expression Regulation, Neoplastic ; Glioma/genetics ; Glioma/metabolism ; Glioma/veterinary ; Humans ; Lymphoma, B-Cell/genetics ; Lymphoma, B-Cell/metabolism ; Lymphoma, B-Cell/veterinary ; Neoplasms/metabolism ; Oncogene Fusion ; Oncogene Proteins, Fusion/metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Translocation, Genetic
Czasopismo naukowe
Tytuł :
Panel OKs CAR T Therapy for Leukemia.
Źródło :
Cancer discovery [Cancer Discov] 2017 Sep; Vol. 7 (9), pp. 924. Date of Electronic Publication: 2017 Jul 27.
Typ publikacji :
Journal Article
MeSH Terms :
Leukemia/*drug therapy
Oncogene Proteins, Fusion/*therapeutic use
Receptors, Antigen, T-Cell/*therapeutic use
Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Leukemia/immunology ; Male ; Oncogene Proteins, Fusion/immunology ; Receptors, Antigen, T-Cell/immunology ; T-Lymphocytes/immunology ; Young Adult
Czasopismo naukowe
Tytuł :
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.
Autorzy :
Vaishnavi A; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Schubert L; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Rix U; Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Marek LA; Department of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado.
Le AT; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Keysar SB; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Glogowska MJ; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Smith MA; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Kako S; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Sumi NJ; Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Davies KD; Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado.
Ware KE; Department of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado.
Varella-Garcia M; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Haura EB; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Jimeno A; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Heasley LE; Department of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado.
Aisner DL; Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado.
Doebele RC; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2017 Jul 01; Vol. 77 (13), pp. 3551-3563. Date of Electronic Publication: 2017 Apr 20.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*enzymology
ErbB Receptors/*metabolism
Lung Neoplasms/*drug therapy
Lung Neoplasms/*enzymology
Oncogene Proteins, Fusion/*metabolism
Small Molecule Libraries/*pharmacology
Animals ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; HEK293 Cells ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Mice ; Mice, Nude ; Oncogene Proteins, Fusion/genetics ; Signal Transduction ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Autorzy :
Drilon A; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. .
Siena S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy.
Ou SI; Chao Family Comprehensive Cancer Center, University of California, Irvine, California.
Patel M; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida.
Ahn MJ; Samsung Medical Center, Seoul, Korea.
Lee J; Samsung Medical Center, Seoul, Korea.
Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee.
Farago AF; Massachusetts General Hospital, Boston, Massachusetts.
Wheler JJ; The University of Texas MD Anderson Cancer Center, Houston, Texas.
Liu SV; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
Doebele R; University of Colorado Cancer Center, Aurora, Colorado.
Giannetta L; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Cerea G; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Marrapese G; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Schirru M; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Amatu A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Bencardino K; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Palmeri L; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Sartore-Bianchi A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Vanzulli A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy.
Cresta S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Damian S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Duca M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Ardini E; Nerviano Medical Sciences s.r.l, Milan, Italy.
Li G; Ignyta, Inc., San Diego, California.
Christiansen J; Ignyta, Inc., San Diego, California.
Kowalski K; Ignyta, Inc., San Diego, California.
Johnson AD; Ignyta, Inc., San Diego, California.
Patel R; Ignyta, Inc., San Diego, California.
Luo D; Ignyta, Inc., San Diego, California.
Chow-Maneval E; Ignyta, Inc., San Diego, California.
Hornby Z; Ignyta, Inc., San Diego, California.
Multani PS; Ignyta, Inc., San Diego, California.
Shaw AT; Massachusetts General Hospital, Boston, Massachusetts.
De Braud FG; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy.; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Pokaż więcej
Źródło :
Cancer discovery [Cancer Discov] 2017 Apr; Vol. 7 (4), pp. 400-409. Date of Electronic Publication: 2017 Feb 09.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Benzamides/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Colorectal Neoplasms/*drug therapy
Indazoles/*administration & dosage
Mammary Analogue Secretory Carcinoma/*drug therapy
Melanoma/*drug therapy
Oncogene Proteins, Fusion/*antagonists & inhibitors
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anaplastic Lymphoma Kinase ; Benzamides/adverse effects ; Benzamides/pharmacokinetics ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Crizotinib ; Dose-Response Relationship, Drug ; Female ; Humans ; Indazoles/adverse effects ; Indazoles/pharmacokinetics ; Male ; Mammary Analogue Secretory Carcinoma/genetics ; Melanoma/genetics ; Melanoma/pathology ; Membrane Glycoproteins/antagonists & inhibitors ; Membrane Glycoproteins/genetics ; Middle Aged ; Oncogene Proteins, Fusion/genetics ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Proto-Oncogene Proteins/antagonists & inhibitors ; Pyrazoles/administration & dosage ; Pyridines/administration & dosage ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors ; Receptor Protein-Tyrosine Kinases/genetics ; Receptor, trkA/antagonists & inhibitors ; Receptor, trkA/genetics ; Receptor, trkB/antagonists & inhibitors ; Receptor, trkB/genetics ; Receptor, trkC/antagonists & inhibitors ; Receptor, trkC/genetics ; Sequestosome-1 Protein/genetics
Czasopismo naukowe
Tytuł :
E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.
Autorzy :
Duque-Afonso J; Department of Pathology, Stanford University School of Medicine, Stanford, California.
Lin CH; Department of Pathology, Stanford University School of Medicine, Stanford, California.
Han K; Department of Genetics, Stanford University School of Medicine, Stanford, California.
Wei MC; Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
Feng J; Department of Pathology, Stanford University School of Medicine, Stanford, California.; Department of Pathology and Department of Medicine, New York University Langone Medical Center, New York, New York.
Kurzer JH; Department of Pathology, Stanford University School of Medicine, Stanford, California.
Schneidawind C; Department of Pathology, Stanford University School of Medicine, Stanford, California.; Department of Hematology and Oncology, University Hospital Tuebingen, Tuebingen, Germany.
Wong SH; Department of Pathology, Stanford University School of Medicine, Stanford, California.
Bassik MC; Department of Genetics, Stanford University School of Medicine, Stanford, California.
Cleary ML; Department of Pathology, Stanford University School of Medicine, Stanford, California. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2016 Dec 01; Vol. 76 (23), pp. 6937-6949. Date of Electronic Publication: 2016 Oct 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms :
B-Lymphocytes/*metabolism
Homeodomain Proteins/*genetics
Oncogene Proteins, Fusion/*genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*genetics
Animals ; Gene Expression ; Homeodomain Proteins/metabolism ; Humans ; Mice ; Mice, Transgenic ; Oncogene Proteins, Fusion/metabolism ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism ; Signal Transduction
Czasopismo naukowe
Tytuł :
Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia.
Autorzy :
Lopez CK; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Villejuif, France.; Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.
Noguera E; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.; Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.
Stavropoulou V; University Children's Hospital Beider Basel (UKBB) and Department of Biomedicine, University of Basel, Basel, Switzerland.
Robert E; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.; Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.
Aid Z; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.; Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.
Ballerini P; Hôpital Trousseau, AP-HP, Paris, France.
Bilhou-Nabera C; Sorbonne Université, CRSA-Unité INSERM, AP-HP, Hôpital Trousseau, Paris, France.
Lapillonne H; Hôpital Saint Antoine, AP-HP, Paris, France.
Boudia F; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.; Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.; Université Paris Diderot, Paris, France.
Thirant C; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.; Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.
Fagnan A; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.; Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.; Université Paris Diderot, Paris, France.
Arcangeli ML; Unité Mixte de Recherche 967 INSERM, CEA/DRF/IBFJ/IRCM/LSHL, Université Paris-Diderot-Université Paris-Sud, Equipe labellisée Association Recherche Contre le Cancer, Fontenay-aux-roses, France.
Kinston SJ; Wellcome and MRC Cambridge Stem Cell Institute and the Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Diop M; Gustave Roussy, Villejuif, France.
Job B; Gustave Roussy, Villejuif, France.
Lecluse Y; Gustave Roussy, Villejuif, France.
Brunet E; Genome Dynamics in the Immune System Laboratory, Institut Imagine, INSERM, Université Paris Descartes, Sorbonne Paris Cité, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Babin L; Genome Dynamics in the Immune System Laboratory, Institut Imagine, INSERM, Université Paris Descartes, Sorbonne Paris Cité, Equipe Labellisée Ligue Contre le Cancer, Paris, France.
Villeval JL; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.
Delabesse E; INSERM U1037, Team 16, Center of Research of Cancerology of Toulouse, Hematology Laboratory, IUCT-Oncopole, France.
Peters AHFM; Friedrich Miescher Institute for Biomedical Research (FMI), Basel, Switzerland.; Faculty of Sciences, University of Basel, Basel, Switzerland.
Vainchenker W; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.
Gaudry M; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.
Masetti R; Department of Pediatrics, 'Lalla Seràgnoli,' Hematology-Oncology Unit, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Locatelli F; Department of Pediatrics, Sapienza, University of Rome, Rome, Italy.; Hematology-Oncology-IRCCS Ospedale Bambino Gesù, Rome, Italy.
Malinge S; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Villejuif, France.; Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.
Nerlov C; MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Droin N; INSERM U1170, Gustave Roussy, Villejuif, France.
Lobry C; INSERM U1170, Gustave Roussy, Villejuif, France.
Godin I; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.
Bernard OA; INSERM U1170, Gustave Roussy, Villejuif, France.; Gustave Roussy, Villejuif, France.; Université Paris-Saclay, Villejuif, France.; Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.
Göttgens B; Wellcome and MRC Cambridge Stem Cell Institute and the Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Petit A; Hôpital Trousseau, AP-HP, Paris, France.
Pflumio F; Unité Mixte de Recherche 967 INSERM, CEA/DRF/IBFJ/IRCM/LSHL, Université Paris-Diderot-Université Paris-Sud, Equipe labellisée Association Recherche Contre le Cancer, Fontenay-aux-roses, France.
Schwaller J; University Children's Hospital Beider Basel (UKBB) and Department of Biomedicine, University of Basel, Basel, Switzerland. .
Mercher T; INSERM U1170, Gustave Roussy, Villejuif, France. .; Gustave Roussy, Villejuif, France.; Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France.; Université Paris Diderot, Paris, France.
Pokaż więcej
Źródło :
Cancer discovery [Cancer Discov] 2019 Dec; Vol. 9 (12), pp. 1736-1753. Date of Electronic Publication: 2019 Oct 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Myeloid, Acute/*pathology
Oncogene Proteins, Fusion/*genetics
Adolescent ; Age Factors ; Animals ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Leukemia, Myeloid, Acute/genetics ; Mice ; Neoplasm Transplantation ; Transcription Factors ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Oncogenic Drivers and Development.
Autorzy :
Cruz Hernandez D; MRC Molecular Haematology Unit and Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Vyas P; MRC Molecular Haematology Unit and Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom. .
Pokaż więcej
Źródło :
Cancer discovery [Cancer Discov] 2019 Dec; Vol. 9 (12), pp. 1653-1655.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid*
Aged ; Carcinogenesis ; Child ; Child, Preschool ; Humans ; Infant ; Oncogene Proteins, Fusion/genetics ; Phenotype
Czasopismo naukowe
Tytuł :
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Autorzy :
Goyal L; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Shi L; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Liu LY; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Fece de la Cruz F; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Lennerz JK; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Raghavan S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Leschiner I; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Elagina L; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Siravegna G; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.; Department of Oncology, University of Torino, Candiolo, Torino, Italy.
Ng RWS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Vu P; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Patra KC; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Saha SK; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Uppot RN; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Arellano R; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Reyes S; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Sagara T; Tsukuba Research Institute, Taiho Pharmaceutical Co., Ltd., Japan.
Otsuki S; Tsukuba Research Institute, Taiho Pharmaceutical Co., Ltd., Japan.
Nadres B; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Shahzade HA; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Dey-Guha I; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Fetter IJ; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Baiev I; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Van Seventer EE; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Murphy JE; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Ferrone CR; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Tanabe KK; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Deshpande V; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Harding JJ; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Yaeger R; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Kelley RK; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Bardelli A; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.; Department of Oncology, University of Torino, Candiolo, Torino, Italy.
Iafrate AJ; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Benes CH; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Ting DT; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Hirai H; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Getz G; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Juric D; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Zhu AX; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. .
Corcoran RB; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. .
Bardeesy N; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. .; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Pokaż więcej
Źródło :
Cancer discovery [Cancer Discov] 2019 Aug; Vol. 9 (8), pp. 1064-1079. Date of Electronic Publication: 2019 May 20.
Typ publikacji :
Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Adenosine Triphosphate/*metabolism
Cholangiocarcinoma/*genetics
Cholangiocarcinoma/*metabolism
Drug Resistance, Neoplasm/*genetics
Protein Kinase Inhibitors/*pharmacology
Receptor, Fibroblast Growth Factor, Type 2/*antagonists & inhibitors
Receptor, Fibroblast Growth Factor, Type 2/*genetics
Adult ; Aged ; Cell Line, Tumor ; Cholangiocarcinoma/diagnosis ; Circulating Tumor DNA ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Oncogene Proteins, Fusion/antagonists & inhibitors ; Oncogene Proteins, Fusion/genetics ; Phenylurea Compounds/pharmacology ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/pharmacology ; Receptor, Fibroblast Growth Factor, Type 2/chemistry ; Receptor, Fibroblast Growth Factor, Type 2/metabolism ; Signal Transduction/drug effects ; Structure-Activity Relationship ; Tomography, X-Ray Computed
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies